Sophie J Bakri1, Ahmed F Omar. 1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA. bakri.sophie@mayo.edu
Abstract
PURPOSE: To report a case of worsening of vitreomacular traction (VMT) after the dexamethasone intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). CASE: A 71-year-old man who presented with macular edema secondary to CRVO was treated by intravitreal injections of bevacizumab followed by Ozurdex. RESULTS: VMT developed during the course of treatment and became more evident when macular edema resolved after treatment with Ozurdex. CONCLUSION: VMT may become apparent and worsen after resolution of macular edema treated with intravitreal Ozurdex.
PURPOSE: To report a case of worsening of vitreomacular traction (VMT) after the dexamethasone intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). CASE: A 71-year-old man who presented with macular edema secondary to CRVO was treated by intravitreal injections of bevacizumab followed by Ozurdex. RESULTS: VMT developed during the course of treatment and became more evident when macular edema resolved after treatment with Ozurdex. CONCLUSION: VMT may become apparent and worsen after resolution of macular edema treated with intravitreal Ozurdex.
Authors: K Schmitz; M Maier; C R Clemens; F Höhn; J Wachtlin; F Lehmann; T Bertelmann; K Rüdiger; M Horn; A Bezatis; G Spital; C H Meyer Journal: Ophthalmologe Date: 2014-01 Impact factor: 1.059